Drug intelligence / Profile preview

drospirenone

Development stage
Approved
Lead developer
Bayer HealthCare Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Drospirenone is a synthetic progestin used primarily as an oral contraceptive to prevent pregnancy. It is available both as a progestin-only pill (notably under the brand name Slynd) and in combination with estrogens such as ethinyl estradiol or estetrol (as in Yaz and Yasmin) for combined oral contraception. In addition to its contraceptive use, drospirenone-containing products are approved for the treatment of moderate acne vulgaris and premenstrual dysphoric disorder (PMDD), and are also used in menopausal hormone therapy to treat vasomotor symptoms, vaginal atrophy, and help prevent postmenopausal osteoporosis[2][3][5]. Drospirenone acts as an agonist at the progesterone receptor, an antagonist at mineralocorticoid receptors (anti-mineralocorticoid activity), and an antagonist at androgen receptors (antiandrogenic activity)[2][6]. Its anti-mineralocorticoid effect opposes estrogen-induced water retention; its antiandrogenic effect helps reduce acne[2][6]. Drospirenone is structurally related to spironolactone.

Brand names
SlyndYazYasminAngeliq
Other names
DihydrospirorenoneDehydrospirorenoneDrospirenona1,2-DihydrospirorenoneDrospirenonumZK 30595ZK30595ZK-30595ZK‑30595
02

Targets

AR (Adrenergic receptors)PR (Progesterone receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on drospirenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on drospirenone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call